[Federal Register Volume 87, Number 71 (Wednesday, April 13, 2022)]
[Notices]
[Pages 21892-21893]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-07866]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Development of 
Diagnostic for Imaging and Early Detection of Pancreatic Cancer and 
Pre-Cancerous Lesions by Targeting the Cholecystokinin-B Receptor

AGENCY: National Institutes of Health.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an exclusive, sublicensable, patent license 
to Georgetown University ``Georgetown'', a private university located 
in Washington DC, to its rights to the invention embodied in the 
Patents and Patent Applications listed in the Supplementary Information 
section of this notice.

[[Page 21893]]


DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before April 28, 2022 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Whitney Hastings, Ph.D., Senior Technology 
Transfer Manager at <a href="/cdn-cgi/l/email-protection#73041b1a071d160a5d1b1200071a1d140041331d1a1b5d141c05"><span class="__cf_email__" data-cfemail="b3c4dbdac7ddd6ca9ddbd2c0c7daddd4c081f3dddadb9dd4dcc5">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION:

Intellectual Property

    United States Provisional Patent Application No. 63/030,815, filed 
May 27, 2020, entitled ``TARGETING THE CHOLECYSTOKININ-B RECEPTOR FOR 
IMAGING AND EARLY DETECTION OF PANCREATIC CANCER AND PRE-CANCEROUS 
LESIONS,'' [HHS Ref. No. E--184-2020-0].
    The patent rights in these inventions have been assigned to the 
Government of the United States of America and Georgetown University. 
The prospective patent license will be for the purpose of consolidating 
the patent rights to Georgetown, the co-owner of said rights, for 
commercial development and marketing. Consolidation of these co-owned 
rights is intended to expedite development of the invention, consistent 
with the goals of the Bayh-Dole Act codified as 35 U.S.C. 200-212.
    The prospective patent license will be worldwide, exclusive, and 
may be limited to those fields of use commensurate in scope with the 
patent rights. It will be sublicensable, and any sublicenses granted by 
Georgetown will be subject to the provisions of 37 CFR part 401 and 
404.
    This technology discloses a method of detecting the presence of a 
pancreatic intraepithelial neoplasia lesion in vivo via administering 
to the subject a construct, or a pharmaceutically acceptable salt 
thereof, wherein the construct is comprised of siRNA-polymer 
nanoparticle complex that selectively bind to cholecystokinin-B 
receptors. The nanoparticle can be conjugated with a fluorophore or 
radioactive molecule (e.g., technetium). In conjunction with an imaging 
device, the polyplex nanoparticle could be used to detect the presence 
of precancerous pancreatic intraepithelial neoplasia (PanIN) lesions.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: April 7, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2022-07866 Filed 4-12-22; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>